Mesenchymal Stem Cell-Based Therapy for Cerebellar Ataxia: From Bench to Bedside

Area of Science:

• Neuroscience
• Regenerative Medicine
• Stem Cell Biology

Background:

• Cerebellar ataxia (CA) is a group of debilitating neurological disorders characterized by Purkinje cell loss and neuroinflammation, with no current disease-modifying therapies.
• Human mesenchymal stem cells (hMSCs) possess neuroprotective and immunomodulatory properties via paracrine secretion, making them a potential therapeutic candidate for CA.

Purpose of the Study:

• To review preclinical and clinical evidence evaluating the efficacy of human mesenchymal stem cells (hMSCs) for treating various forms of cerebellar ataxia (CA).
• To assess the potential of hMSC therapy in mitigating core pathological mechanisms of CA, including neuroinflammation and Purkinje cell degeneration.

Main Methods:

• Systematic literature search of preclinical and clinical studies on hMSC therapy for CA from 2000-2026 in major databases (PubMed/MEDLINE, Embase, Cochrane Library).
• Inclusion of in vivo animal models (LPS-induced, Ara-C-induced, SCA2 transgenic) and human clinical data (trials, case reports) focusing on motor function, Purkinje cell integrity, and neuroinflammation.
• Analysis of hMSC secretome capacity in CA patients versus healthy donors to inform therapeutic strategies.

Main Results:

• hMSC transplantation demonstrated consistent improvements in motor function, preserved Purkinje cell integrity, and reduced neuroinflammation across diverse CA models.
• MSCs derived from CA patients showed diminished anti-inflammatory capacity, supporting the use of allogeneic hMSC transplantation.
• Therapeutic benefits of hMSC therapy were observed even when administered after symptom onset in a spinocerebellar ataxia type 2 (SCA2) model.

Conclusions:

• hMSC therapy effectively targets key CA pathomechanisms, including microglial suppression and neurotrophin restoration, primarily through paracrine signaling.
• The demonstrated post-symptomatic efficacy and growing clinical evidence base warrant progression to placebo-controlled randomized trials for hMSC-based CA treatments.